Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 887-893

  Van Den Eynde, Eva ^a   Quer, Josep ^a,b   Cubero, María ^a,b   Curran, Adriá ^a   Homs, María ^a,b   Garcia Cehic, Damir ^a,b   Falco, Vicenç ^a   Ribera, Esteban ^a   Esteban, Juan I ^a,b   Pahissa, Albert ^a   Crespo, Manuel ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; RIBAVIRIN; TENOFOVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CLONE; CELL STRAIN HUH 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; GENOTYPE; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; RNA SYNTHESIS; VIRUS CELL INTERACTION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HUMANS; INTERFERONS; REPLICON; RIBAVIRIN; RNA, VIRAL;

EID: 80052934153     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1861     Document Type: Article

References (41)

1. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
3. Sulkowski MS. The HIV-coinfected patient: managing viral hepatitis. J Acquir Immune Defic Syndr 2007; 45 Suppl 2:S36-S37. (Pubitemid 47294914)
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497. (Pubitemid 32173638)
5. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
6. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
7. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
9. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848. (Pubitemid 39628231)
10. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459. (Pubitemid 38988594)
11. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36. (Pubitemid 39179626)
12. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14:228-238. (Pubitemid 46452410)
13. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49:22-31.
14. Solà R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 2006; 22:393-400. (Pubitemid 43787763)
15. Pineda JA, Mira JA, Gil IL, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354. (Pubitemid 350168332)
16. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47:36-49. (Pubitemid 351619367)
17. Balzarini J, Lee CK, Herdewijn P, De CE. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266:21509-21514.
18. Laguno M, Milinkovic A, de Lazzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10:423-429. (Pubitemid 41151020)
19. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-1236. (Pubitemid 27231419)
20. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-1379. (Pubitemid 17041656)
21. Mira JA, Lopez-Cortes LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 2007; 12:1225-1235.
22. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125. (Pubitemid 46684453)
23. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
24. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437. (Pubitemid 352016736)
25. Crespo M, Pou L, Esteban JI, et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther 2007; 12:1217-1223.
26. Berenguer J, von Wichmann M, Quereda C. Effect of accompanying antiretroviral drugs on virologic response to PEG-IFN and ribavirin in HIV/HCV co-infected patients. GESIDA 36/03 and 50/06 study. 17th Conference of Retroviruses and opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Poster 663.
27. Amorosa VK, Slim J, Mounzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010; 15:91-99.
28. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13: 953-957.
29. Van den Eynde E, Tiraboschi JM, Tural C, et al. Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS 2010; 24:975-982.
30. Pietschmann T, Lohmann V, Kaul A, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002; 76:4008-4021. (Pubitemid 34250565)
31. Kato T, Date T, Miyamoto M, et al. Detection of antihepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 2005; 43:5679-5684. (Pubitemid 41612348)
32. Tanabe Y, Sakamoto N, Enomoto N, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004; 189:1129-1139. (Pubitemid 38457235)
33. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47:23-30. (Pubitemid 46817685)
34. Margot NA, Miller MD. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther 2005; 10:343-348.
35. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004; 9:133-138. (Pubitemid 38313956)
36. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon - ribavirin combination treatment. Clin Infect Dis 2005; 41:1806-1809. (Pubitemid 41759869)
37. Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. AIDS Res Hum Retroviruses 1998; 14:1661-1667. (Pubitemid 28563857)
38. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine MD. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14:1857-1858.
39. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus - hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49:3997-4008. (Pubitemid 41400938)
40. Asahina Y, Izumi N, Enomoto N, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43:623-629. (Pubitemid 41253229)
41. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-1009. (Pubitemid 34453997)